{
  "first_published_at": "2010-11-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON099863", 
  "title": "Tamoxifen for breast cancer: drug interactions involving CYP2D6, genetic variants, and variability in clinical response", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 177, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Tamoxifen for breast cancer: drug interactions involving CYP2D6, genetic variants, and variability in clinical response</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><em>CYP2D6</em> genetic polymorphisms and concomitant use of potent CYP2D6 inhibitors may be associated with variability in clinical response in patients treated with tamoxifen for breast cancer. Therefore, concomitant use of medicines known to be potent CYP2D6 inhibitors should be avoided whenever possible in patients treated with tamoxifen. Current data for the effect of genetic polymorphisms are insufficient to support recommending genotyping of patients.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Tamoxifen is a selective oestrogen-receptor modulator indicated for palliative and adjuvant treatment of oestrogen-receptor-positive breast cancer in premenopausal and postmenopausal women. Tamoxifen is a prodrug, and the formation of the active metabolite, endoxifen, is mediated by the CYP2D6 enzyme. Several articles have recently been published regarding the potential effect of <em>CYP2D6</em> genetic variants on clinical response to tamoxifen treatment in patients with breast cancer.</p><p>In patients with inherited non-functional alleles of the <em>CYP2D6</em> gene (&lsquo;poor metabolisers&rsquo;) or in patients concomitantly treated with CYP2D6 enzyme inhibitors, concentrations of the tamoxifen metabolites that most strongly bind to the oestrogen receptor may be reduced.</p><h2>Effect of tamoxifen in patients treated with potent CYP2D6 inhibitors</h2><p>A population-based cohort study on SSRI antidepressants and breast-cancer mortality in women receiving tamoxifen found that the risk of death from breast cancer increased with the length of concomitant treatment with paroxetine&mdash;a potent inhibitor of CYP2D6, but not with other SSRIs. The proportion of time on tamoxifen with overlapping use of paroxetine of 25%, 50%, and 75% was associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively.<cite>Kelly CM, et al. BMJ 2010; 340: c693.</cite></p><p>A more-recent study<cite>Dezentje VO, et al. J Clin Oncol 2010; 28: 2423&ndash;29.</cite>found no evidence for decreased efficacy with the co-administration of CYP2D6 inhibitors and tamoxifen, but given the strong mechanistic model and overall weight of evidence it is recommended that strong CYP2D6 inhibitors should be avoided whenever possible in patients taking tamoxifen. Examples of such drugs include <strong>paroxetine, fluoxetine, bupropion, quinidine, and cinacalcet</strong>.</p><h2>Association of <em>CYP2D6</em> polymorphism status with poor clinical outcome</h2><p>The evidence linking various poor metaboliser genotypes and tamoxifen treatment outcomes is mixed and inconclusive. Therefore there is no current recommendation for genetic testing&nbsp;before treatment with tamoxifen.<cite>Schroth W, et al. JAMA 2009; 302: 1429&ndash;36.</cite><cite>Goetz MP, et al. Breast Cancer Res Treat 2007; 101: 113&ndash;21.</cite><cite>Goetz MP, et al. J Clin Oncol 2005; 23: 9312&ndash;18.</cite><cite>Schroth W, et al. J Clin Oncol 2007; 25: 5187&ndash;93.</cite><cite>Bonanni B, et al. J Clin Oncol 2006; 24: 3708&ndash;09.</cite><cite>Newman WG, et al. Clin Cancer Res 2008, 14: 5913&ndash;18.</cite><cite>Nowell SA. Breast Cancer Res Treat 2005; 91: 249&ndash;58.</cite><cite>Wegman P, et al. Breast Cancer Res 2005; 7: R284&ndash;90.</cite><cite>Wegman P. Breast Cancer Res 2007; 9: R7.</cite><cite>Abraham JE, et al. Breast Cancer Res 2010; 12: R64.</cite></p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Concomitant use of drugs that are potent inhibitors&nbsp;of the&nbsp;CYP2D6 enzyme should be avoided whenever possible in patients treated with tamoxifen for breast cancer</li>\r\n\t\t\t\t<li>Current data for the effect of genetic polymorphisms are insufficient to support recommending genotyping of patients</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong> is available in a <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097444.pdf\" target=\"_blank\">report from the September 2010 meeting of the European Pharmacovigilance Working Party</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Nov 2010 vol 4, issue 4: A1.</em>&nbsp;</p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Tamoxifen is a selective oestrogen-receptor modulator indicated for palliative and adjuvant treatment of oestrogen-receptor-positive breast cancer in premenopausal and postmenopausal women. Tamoxifen is a prodrug, and the formation of the active metabolite, endoxifen, is mediated by the CYP2D6 enzyme. Several articles have recently been published regarding the potential effect of <em>CYP2D6</em> genetic variants on clinical response to tamoxifen treatment in patients with breast cancer.</p><p>In patients with inherited non-functional alleles of the <em>CYP2D6</em> gene (&#8216;poor metabolisers&#8217;) or in patients concomitantly treated with CYP2D6 enzyme inhibitors, concentrations of the tamoxifen metabolites that most strongly bind to the oestrogen receptor may be reduced.</p><h2>Effect of tamoxifen in patients treated with potent CYP2D6 inhibitors</h2><p>A population-based cohort study on SSRI antidepressants and breast-cancer mortality in women receiving tamoxifen found that the risk of death from breast cancer increased with the length of concomitant treatment with paroxetine&#8212;a potent inhibitor of CYP2D6, but not with other SSRIs. The proportion of time on tamoxifen with overlapping use of paroxetine of 25%, 50%, and 75% was associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively.<cite>Kelly CM, et al. BMJ 2010; 340: c693.</cite></p><p>A more-recent study<cite>Dezentje VO, et al. J Clin Oncol 2010; 28: 2423&#8211;29.</cite>found no evidence for decreased efficacy with the co-administration of CYP2D6 inhibitors and tamoxifen, but given the strong mechanistic model and overall weight of evidence it is recommended that strong CYP2D6 inhibitors should be avoided whenever possible in patients taking tamoxifen. Examples of such drugs include <strong>paroxetine, fluoxetine, bupropion, quinidine, and cinacalcet</strong>.</p><h2>Association of <em>CYP2D6</em> polymorphism status with poor clinical outcome</h2><p>The evidence linking various poor metaboliser genotypes and tamoxifen treatment outcomes is mixed and inconclusive. Therefore there is no current recommendation for genetic testing&#160;before treatment with tamoxifen.<cite>Schroth W, et al. JAMA 2009; 302: 1429&#8211;36.</cite><cite>Goetz MP, et al. Breast Cancer Res Treat 2007; 101: 113&#8211;21.</cite><cite>Goetz MP, et al. J Clin Oncol 2005; 23: 9312&#8211;18.</cite><cite>Schroth W, et al. J Clin Oncol 2007; 25: 5187&#8211;93.</cite><cite>Bonanni B, et al. J Clin Oncol 2006; 24: 3708&#8211;09.</cite><cite>Newman WG, et al. Clin Cancer Res 2008, 14: 5913&#8211;18.</cite><cite>Nowell SA. Breast Cancer Res Treat 2005; 91: 249&#8211;58.</cite><cite>Wegman P, et al. Breast Cancer Res 2005; 7: R284&#8211;90.</cite><cite>Wegman P. Breast Cancer Res 2007; 9: R7.</cite><cite>Abraham JE, et al. Breast Cancer Res 2010; 12: R64.</cite></p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Concomitant use of drugs that are potent inhibitors&#160;of the&#160;CYP2D6 enzyme should be avoided whenever possible in patients treated with tamoxifen for breast cancer</li>\r\n\t\t\t\t<li>Current data for the effect of genetic polymorphisms are insufficient to support recommending genotyping of patients</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong> is available in a <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097444.pdf\" target=\"_blank\">report from the September 2010 meeting of the European Pharmacovigilance Working Party</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Nov 2010 vol 4, issue 4: A1.</em>&#160;</p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-11-01", 
  "date_last_modified": "2010-11-18", 
  "_assets": [], 
  "_item_id": 177, 
  "summary": "CYP2D6 genetic polymorphisms and concomitant use of potent CYP2D6 inhibitors may be associated with variability in clinical response in patients treated with tamoxifen for breast cancer. Therefore, concomitant use of medicines known to be potent CYP2D6 inhibitors should be avoided whenever possible in patients treated with tamoxifen. Current data for the effect of genetic polymorphisms are insufficient to support recommending genotyping of patients.", 
  "body": "Article date: November 2010\n\nTamoxifen is a selective oestrogen-receptor modulator indicated for palliative and adjuvant treatment of oestrogen-receptor-positive breast cancer in premenopausal and postmenopausal women. Tamoxifen is a prodrug, and the formation of the active metabolite, endoxifen, is mediated by the CYP2D6 enzyme. Several articles have recently been published regarding the potential effect of CYP2D6 genetic variants on clinical response to tamoxifen treatment in patients with breast cancer.\n\nIn patients with inherited non-functional alleles of the CYP2D6 gene (‘poor metabolisers’) or in patients concomitantly treated with CYP2D6 enzyme inhibitors, concentrations of the tamoxifen metabolites that most strongly bind to the oestrogen receptor may be reduced.\n\n## Effect of tamoxifen in patients treated with potent CYP2D6 inhibitors\n\nA population-based cohort study on SSRI antidepressants and breast-cancer mortality in women receiving tamoxifen found that the risk of death from breast cancer increased with the length of concomitant treatment with paroxetine—a potent inhibitor of CYP2D6, but not with other SSRIs. The proportion of time on tamoxifen with overlapping use of paroxetine of 25%, 50%, and 75% was associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively.[^1]\n\nA more-recent study[^2]found no evidence for decreased efficacy with the co-administration of CYP2D6 inhibitors and tamoxifen, but given the strong mechanistic model and overall weight of evidence it is recommended that strong CYP2D6 inhibitors should be avoided whenever possible in patients taking tamoxifen. Examples of such drugs include paroxetine, fluoxetine, bupropion, quinidine, and cinacalcet.\n\n## Association of CYP2D6 polymorphism status with poor clinical outcome\n\nThe evidence linking various poor metaboliser genotypes and tamoxifen treatment outcomes is mixed and inconclusive. Therefore there is no current recommendation for genetic testing before treatment with tamoxifen.[^3] [^4] [^5] [^6] [^7] [^8] [^9] [^10] [^11] [^12]\n\nAdvice for healthcare professionals:  \n  \n  * Concomitant use of drugs that are potent inhibitors of the CYP2D6 enzyme should be avoided whenever possible in patients treated with tamoxifen for breast cancer  \n  * Current data for the effect of genetic polymorphisms are insufficient to support recommending genotyping of patients  \n  \nFurther information is available in a [report from the September 2010 meeting of the European Pharmacovigilance Working Party](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097444.pdf)\n\n \n\nArticle citation: Drug Safety Update Nov 2010 vol 4, issue 4: A1. \n\n[^1]: Kelly CM, et al. BMJ 2010; 340: c693.\n\n[^2]: Dezentje VO, et al. J Clin Oncol 2010; 28: 2423–29.\n\n[^3]: Schroth W, et al. JAMA 2009; 302: 1429–36.\n\n[^4]: Goetz MP, et al. Breast Cancer Res Treat 2007; 101: 113–21.\n\n[^5]: Goetz MP, et al. J Clin Oncol 2005; 23: 9312–18.\n\n[^6]: Schroth W, et al. J Clin Oncol 2007; 25: 5187–93.\n\n[^7]: Bonanni B, et al. J Clin Oncol 2006; 24: 3708–09.\n\n[^8]: Newman WG, et al. Clin Cancer Res 2008, 14: 5913–18.\n\n[^9]: Nowell SA. Breast Cancer Res Treat 2005; 91: 249–58.\n\n[^10]: Wegman P, et al. Breast Cancer Res 2005; 7: R284–90.\n\n[^11]: Wegman P. Breast Cancer Res 2007; 9: R7.\n\n[^12]: Abraham JE, et al. Breast Cancer Res 2010; 12: R64.\n"
}